MeSH term
Frequency | Condition_Probility | Animals | 66 | 0.0 |
Humans | 176 | 0.0 |
Research Support, Non-U.S. Gov't | 123 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Cell Cycle | 13 | 1.0 |
Enzyme Activation | 15 | 0.0 |
Hydrolysis | 2 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Phosphorylation | 56 | 0.0 |
Protein Kinases/genetics/*metabolism | 3 | 3.0 |
Xenopus | 2 | 0.0 |
cdc25 Phosphatase/*metabolism | 15 | 39.0 |
Aged | 7 | 0.0 |
Cell Cycle/physiology | 7 | 2.0 |
Cell Cycle Proteins/*metabolism | 10 | 2.0 |
Cell Differentiation | 6 | 0.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Male | 13 | 0.0 |
Middle Aged | 9 | 0.0 |
Prognosis | 7 | 0.0 |
DNA Primers | 5 | 0.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Female | 27 | 0.0 |
Papillomavirus, Human/genetics | 2 | 5.0 |
*Repressor Proteins | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 16 | 0.0 |
3T3 Cells | 10 | 0.0 |
Mice | 34 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
Proto-Oncogene Proteins c-myc/*genetics | 2 | 4.0 |
MAP Kinase Kinase 1 | 3 | 1.0 |
Oligonucleotide Array Sequence Analysis | 7 | 0.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Tumor Cells, Cultured | 47 | 0.0 |
Amino Acid Motifs | 5 | 0.0 |
Binding Sites | 15 | 0.0 |
Cell Cycle/drug effects | 9 | 1.0 |
Cell Division/drug effects | 15 | 0.0 |
Kinetics | 15 | 0.0 |
Models, Molecular | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 58 | 0.0 |
cdc25 Phosphatase/*antagonists & inhibitors/chemistry | 2 | 100.0 |
Cell Line, Tumor | 9 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 13 | 1.0 |
Amino Acid Sequence | 19 | 0.0 |
Molecular Sequence Data | 26 | 0.0 |
Protein Conformation | 3 | 0.0 |
Protein Kinases/*metabolism | 5 | 1.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Substrate Specificity | 7 | 0.0 |
Base Sequence | 18 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Catalysis | 4 | 0.0 |
Catalytic Domain | 2 | 0.0 |
cdc25 Phosphatase/chemistry/*metabolism | 4 | 57.0 |
Glutathione Transferase/metabolism | 4 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
*CDC2-CDC28 Kinases | 23 | 3.0 |
*Cell Cycle | 3 | 1.0 |
*Cell Cycle Proteins | 14 | 1.0 |
Cell Division | 9 | 0.0 |
Cells, Cultured | 13 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 15 | 4.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Protein Binding | 14 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 13 | 3.0 |
Transcription Factors/metabolism | 4 | 0.0 |
Transfection | 15 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 3 | 1.0 |
Blotting, Northern | 5 | 0.0 |
Blotting, Western | 21 | 0.0 |
Cyclin E/metabolism | 12 | 10.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors | 2 | 1.0 |
Cyclins/metabolism | 8 | 1.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
Down-Regulation | 8 | 0.0 |
Dyes/pharmacology | 2 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Models, Biological | 11 | 0.0 |
Models, Chemical | 5 | 1.0 |
Precipitin Tests | 9 | 0.0 |
Protein Kinases/metabolism | 12 | 2.0 |
Time Factors | 10 | 0.0 |
cdc25 Phosphatase/metabolism | 15 | 28.0 |
Drug Screening Assays, Antitumor | 2 | 0.0 |
Enzyme Inhibitors/*chemical synthesis/chemistry/pharmacology | 3 | 9.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
cdc25 Phosphatase/*antagonists & inhibitors/metabolism | 5 | 100.0 |
Cell Cycle/*physiology | 7 | 2.0 |
Cell Division/physiology | 6 | 0.0 |
DNA/biosynthesis | 4 | 0.0 |
English Abstract | 3 | 0.0 |
G2 Phase/physiology | 2 | 7.0 |
Hela Cells | 20 | 0.0 |
S Phase/physiology | 6 | 7.0 |
p38 Mitogen-Activated Protein Kinases/*physiology | 2 | 50.0 |
Comparative Study | 12 | 0.0 |
Enzyme Stability | 2 | 1.0 |
Mutation | 9 | 0.0 |
Ultraviolet Rays | 8 | 1.0 |
Inhibitory Concentration 50 | 5 | 1.0 |
Molecular Structure | 4 | 0.0 |
cdc25 Phosphatase/*antagonists & inhibitors | 4 | 57.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/metabolism | 3 | 5.0 |
Drug Interactions | 2 | 0.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Phosphorylation/drug effects | 3 | 0.0 |
*Proto-Oncogene Proteins | 9 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Cell Cycle/drug effects/*physiology | 3 | 6.0 |
Estradiol/pharmacology | 2 | 0.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Chromones/pharmacology | 2 | 0.0 |
Embryo/cytology | 3 | 4.0 |
Gene Expression Regulation | 5 | 0.0 |
Genes, myc | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Morpholines/pharmacology | 2 | 0.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Rats | 9 | 0.0 |
Sirolimus/pharmacology | 2 | 2.0 |
cdc25 Phosphatase/*physiology | 2 | 40.0 |
Aged, 80 and over | 4 | 0.0 |
Cell Cycle Proteins/genetics/*metabolism | 4 | 2.0 |
DNA Primers/chemistry | 3 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 2 | 1.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
RNA, Neoplasm/analysis | 4 | 1.0 |
cdc25 Phosphatase/genetics/*metabolism | 12 | 75.0 |
Antibiotics, Antineoplastic/*pharmacology | 2 | 1.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
Cell Cycle Proteins/metabolism | 7 | 2.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors/*metabolism | 5 | 10.0 |
Protein-Tyrosine Kinase/metabolism | 3 | 0.0 |
*Tumor Suppressor Proteins | 9 | 0.0 |
Tyrosine/metabolism | 3 | 0.0 |
*Apoptosis | 5 | 0.0 |
COS Cells | 2 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Gene Targeting | 3 | 0.0 |
Mice, Inbred C57BL | 4 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
*Carrier Proteins | 7 | 1.0 |
Consensus Sequence | 2 | 0.0 |
Promoter Regions (Genetics) | 9 | 0.0 |
cdc25 Phosphatase/biosynthesis/*genetics | 3 | 100.0 |
Adult | 8 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Colon/metabolism | 2 | 1.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Protein Isoforms | 2 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Survival Rate | 3 | 0.0 |
Cell Line | 19 | 0.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Radiation, Ionizing | 8 | 5.0 |
S Phase/radiation effects | 4 | 28.0 |
Serine/metabolism | 5 | 1.0 |
Signal Transduction | 8 | 0.0 |
cdc25 Phosphatase/*physiology/radiation effects | 2 | 100.0 |
Butadienes/pharmacology | 2 | 3.0 |
Nitriles/pharmacology | 2 | 1.0 |
*Signal Transduction | 2 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Cell Cycle Proteins/*analysis | 2 | 11.0 |
Multivariate Analysis | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
cdc25 Phosphatase/*analysis | 2 | 100.0 |
Cattle | 4 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
Xenopus laevis | 3 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Up-Regulation | 4 | 0.0 |
Biopsy | 2 | 0.0 |
Cyclin D1/biosynthesis | 2 | 4.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Ki-67 Antigen/biosynthesis | 2 | 2.0 |
cdc25 Phosphatase/biosynthesis/*metabolism | 2 | 100.0 |
Adenoviridae/genetics | 3 | 0.0 |
Cyclin D1/metabolism | 3 | 2.0 |
Cyclin-Dependent Kinases/*antagonists & inhibitors/metabolism | 2 | 5.0 |
Cyclins/genetics | 2 | 1.0 |
Microtubule-Associated Proteins/metabolism | 4 | 2.0 |
Protein p16 | 2 | 1.0 |
Sequence Alignment | 3 | 0.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 2 | 1.0 |
Apoptosis | 5 | 0.0 |
Cell Cycle Proteins/*genetics | 3 | 1.0 |
Cell Separation | 3 | 0.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
Flow Cytometry | 9 | 0.0 |
G1 Phase | 9 | 2.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Jurkat Cells | 3 | 0.0 |
S Phase | 11 | 3.0 |
DNA, Complementary | 4 | 0.0 |
Mitosis/*physiology | 3 | 3.0 |
Cyclin E/*metabolism | 2 | 5.0 |
Protein Kinase Inhibitors | 4 | 3.0 |
Protein-Serine-Threonine Kinases/*metabolism | 8 | 1.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
14-3-3 Proteins | 3 | 2.0 |
*Muscle Proteins | 2 | 0.0 |
Protein Kinases/metabolism/radiation effects | 2 | 50.0 |
*Tyrosine 3-Monooxygenase | 3 | 6.0 |
cdc25 Phosphatase/metabolism/radiation effects | 2 | 100.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 5 | 0.0 |
*Proteins | 5 | 1.0 |
Histone Deacetylases/*metabolism | 2 | 1.0 |
Cell Differentiation/drug effects | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Carcinogens/pharmacology | 2 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
U937 Cells | 3 | 0.0 |
Tumor Markers, Biological/biosynthesis | 2 | 5.0 |
Cell Survival | 2 | 0.0 |
*DNA Damage | 3 | 0.0 |
DNA Repair | 2 | 0.0 |
DNA Replication | 4 | 1.0 |
Protein p53/metabolism | 5 | 0.0 |
Signal Transduction/*physiology | 3 | 0.0 |
Trans-Activators/genetics | 2 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 5 | 1.0 |
G1 Phase/*drug effects | 3 | 3.0 |
Mitosis/physiology | 2 | 2.0 |
Cell Cycle Proteins/*antagonists & inhibitors | 2 | 33.0 |
Protein Isoforms/metabolism | 2 | 1.0 |
*Xenopus Proteins | 2 | 0.0 |
cdc25 Phosphatase/antagonists & inhibitors/genetics/metabolism | 2 | 100.0 |
Cell Nucleus/enzymology | 2 | 2.0 |
Computer Simulation | 2 | 0.0 |
Feedback | 2 | 1.0 |
G1 Phase/physiology | 8 | 10.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
cdc25 Phosphatase/physiology | 2 | 33.0 |
Threonine/metabolism | 2 | 2.0 |
Apoptosis/*genetics | 2 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
Caspases/metabolism | 2 | 0.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Poly(ADP-ribose) Polymerases/metabolism | 2 | 1.0 |
Cyclins/genetics/*metabolism | 6 | 7.0 |
Granulocytes/metabolism/pathology | 4 | 100.0 |
Leukemia, Myelocytic, Acute/genetics/*metabolism/*pathology | 4 | 100.0 |
Retinoblastoma Protein/genetics/*metabolism | 4 | 9.0 |
Interferon-alpha/*pharmacology | 3 | 2.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Gene Expression | 7 | 0.0 |
Genetic Vectors | 3 | 0.0 |
*cdc25 Phosphatase | 25 | 52.0 |
Protein-Tyrosine-Phosphatase/genetics/*metabolism | 3 | 6.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
S Phase/*physiology | 3 | 6.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Cyclin A/metabolism | 3 | 3.0 |
Cyclin-Dependent Kinases/*metabolism | 5 | 1.0 |
*Genes, myc | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/*genetics | 4 | 3.0 |
DNA Damage | 7 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Proteins/*physiology | 3 | 1.0 |
Protein-Tyrosine-Phosphatase/metabolism | 4 | 3.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Cyclins/*metabolism | 5 | 1.0 |
Protein-Tyrosine-Phosphatase/*biosynthesis | 3 | 75.0 |
*Gene Expression Regulation | 4 | 0.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 3 | 0.0 |
Cysteine Endopeptidases/*metabolism | 3 | 1.0 |
Mitosis | 2 | 0.0 |
Multienzyme Complexes/*metabolism | 3 | 2.0 |
Phosphoprotein Phosphatase/*metabolism | 3 | 3.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
*Down-Regulation | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/metabolism | 2 | 2.0 |
Cell Line, Transformed | 2 | 0.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
cdc25 Phosphatase | 20 | 41.0 |
Cell Cycle Proteins/genetics/metabolism | 3 | 4.0 |
Fibroblasts | 2 | 0.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Protein-Tyrosine-Phosphatase/genetics | 2 | 6.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Cell Cycle Proteins/genetics | 2 | 2.0 |
In Vitro | 3 | 0.0 |
Phosphoprotein Phosphatase/genetics | 2 | 12.0 |
DNA-Binding Proteins/metabolism | 4 | 0.0 |
Mice, Nude | 3 | 0.0 |
Cyclin-Dependent Kinases/genetics/*metabolism | 2 | 3.0 |
DNA Replication/physiology | 2 | 6.0 |
Neoplasm Transplantation | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/*metabolism | 4 | 3.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 4 | 4.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
DNA | 2 | 0.0 |
*S Phase | 4 | 6.0 |
Cell Cycle Proteins/genetics/immunology/*metabolism | 2 | 50.0 |
Phosphoprotein Phosphatase/genetics/immunology/*metabolism | 2 | 100.0 |
Breast Neoplasms/genetics | 2 | 0.0 |
S Phase/*drug effects/physiology | 2 | 66.0 |
S Phase/drug effects | 2 | 3.0 |
Phosphoprotein Phosphatase/genetics/*metabolism | 2 | 11.0 |
Cell Cycle Proteins/*genetics/metabolism | 3 | 5.0 |
Oncogenes/genetics | 2 | 2.0 |
Phosphoprotein Phosphatase/*genetics/metabolism | 2 | 22.0 |
Binding, Competitive | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
G1 Phase/drug effects | 2 | 1.0 |
Phosphoprotein Phosphatase/*genetics | 2 | 5.0 |
Case-Control Studies | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
DNA/metabolism | 3 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Antibiotics, Antineoplastic/pharmacology | 2 | 2.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Camptothecin/pharmacology | 3 | 6.0 |
Etoposide/pharmacology | 2 | 1.0 |
Dimerization | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics | 3 | 1.0 |
Cell Compartmentation | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Ubiquitin/metabolism | 4 | 1.0 |
beta-Transducin Repeat-Containing Proteins/*metabolism | 2 | 100.0 |
Trypsin/pharmacology | 2 | 1.0 |
*Mitosis | 2 | 1.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
*DNA Damage/radiation effects | 2 | 20.0 |
Cell Division/*physiology | 2 | 1.0 |
Phosphoric Monoester Hydrolases/metabolism | 2 | 2.0 |
CDC2-CDC28 Kinases/*metabolism | 3 | 17.0 |
Telomerase/genetics | 2 | 12.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 2 | 2.0 |
Doxorubicin/pharmacology | 2 | 0.0 |
Cyclin B/metabolism | 2 | 2.0 |
DNA Replication/radiation effects | 3 | 25.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Protein Interaction Mapping | 2 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Apoptosis/drug effects/*genetics/radiation effects | 2 | 66.0 |
*G2 Phase | 2 | 5.0 |
Cell Cycle/*physiology/radiation effects | 2 | 50.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
*S Phase/radiation effects | 2 | 66.0 |